CJC-1295 + Ipamorelin Blend
A combined GHRH analog and ghrelin-receptor agonist preparation used in secretagogue research.
From$79.00Select size
Ipamorelin
CAS170851-70-4
A selective ghrelin-receptor agonist studied in growth-hormone release research.
- Test methods
- HPLC-UV + LC-MS
- Purity target
- 99%+ verified
- Sizes available
- 3
- Availability
- In stock
Select size
Quantity
1
Total
$46.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Certificate for this lot is pending. Every batch we ship is published at /coa before it goes out.
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
✦ Research Notes
Background & literature
Origin
Ipamorelin was described in 1998 by a group at Novo Nordisk and introduced in the literature as “the first selective growth hormone secretagogue.” The selectivity claim is the historically interesting part: earlier secretagogues in this class also produced measurable effects on other pituitary hormones, and ipamorelin was characterised as acting on growth-hormone release without that broader profile in the models tested. It is a synthetic pentapeptide.
What has been characterised
Characterised as an agonist at the ghrelin receptor (GHS-R1a) — a ghrelin mimetic — on anterior pituitary cells. Subsequent preclinical work examined it in rodent models, including a rat model of postoperative ileus, and in studies of nitrogen balance and urea synthesis. This is animal and in-vitro pharmacology. Ipamorelin is not FDA-approved for any human use, and growth-hormone secretagogues appear on the WADA Prohibited List.
Sources
- 1.“Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol, 1998. PMID 9849822
- 2.“Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.” J Pharmacol Exp Ther, 2009. PMID 19289567
- 3.WADA Prohibited List — World Anti-Doping Agency
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Batch releases & restocks
Know when the next batch is tested
We publish an independent certificate for every lot before it ships. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.
Related Compounds
HCG
A glycoprotein gonadotropin studied in receptor-binding and endocrine-signalling research models.
From$42.00Notify me
Sermorelin
A GHRH(1-29) analog examined in endocrine and pituitary-signalling research.
From$49.00Notify me
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.